Oncomine Clinical Research Grant program
Together, let’s help shape the future of precision medicine
Thermo Fisher Scientific values and supports independent research to promote excellence in molecular profiling

The Oncomine Clinical Research Grant program supports investigator-initiated studies (IIS) and education projects in oncology research, with the goal to increase high-quality molecular profiling and to help democratize access to sequencing technologies.

Our global network of Oncomine Clinical Research Grant awardees

Since the program’s inception in 2020, the Oncomine Clinical Research Grant program has awarded more than $4 million in funding and instrumentation to labs around the world. Twenty-three grants have been presented to laboratories from 14 different countries across five continents. Previously supported projects have focused on many different aspects of clinical cancer research, with topics in solid tumor, pediatric oncology, hemato-oncology, immuno-oncology, and liquid biopsy research.
“The Oncomine Grant program gives a chance to those who wouldn’t otherwise have it to be able to work with next-generation sequencing technologies. The funding from the Oncomine Grant program can really help us overcome one of the biggest hurdles for smaller and less funded centers to be able to work with these types of emerging technologies.”

—Brandon Sheffield, MD
William Osler Health System, Canada
2020 Oncomine Clinical Research Grant awardee

“Industry funding [like the Oncomine Clinical Research Grant program] is important because it can generate a sort of virtual circle, creating a link between the industry and different academic institutions and hospital research labs, and this link can foster the development and the implementation of new platforms or new assays focused on the unmet clinical needs of the future.”

—Elena Guerini Rocco, MD
European Institute of Oncology IRCCS, Italy
2021 Oncomine Clinical Research Grant awardee

“The opportunity the Oncomine Grant has afforded us to work on the analysis of the T cell repertoire has opened also a number of opportunities for my team to collaborate on larger studies. We are now moving from the analysis that we have done with the Oncomine Grant to a large study at the national level to further evaluate these biomarkers and the T cell repertoire.”

—Elin Gray, PhD
Edith Cowan University, Australia
2021 Oncomine Clinical Research Grant awardee
Application process

The evaluation process is performed by a committee of external experts in the field, along with Thermo Fisher Scientific medical and scientific leadership. The committee selects awardees based on the scientific merit of the proposed project.

Step 1 - Submission
- Submission: Submission is done by sending the proposal form to the following email address: medical.affairs@thermofisher.com or using the online grant management portal.

Step 2 - Evaluation
- Evaluation: Submissions are confirmed by the grant office via email. Decisions are communicated 6 to 8 weeks after the closing date of the call.

Step 3 - Execution
- Execution: Upon contract signature, the requested support will be granted. The grant office team will continue to support the development of the awarded project. A final report is due to the grant office team within the agreed time frame.

“In the long term, our goal is to promote equity of access to molecular profiling in cancer research and further democratize the future of precision medicine.”

—Dr. José Luís Costa
Director, Oncomine Clinical Research Grant program
Thermo Fisher Scientific

2023 program details and deadlines

Thermo Fisher Scientific will host two calls for applications in 2023. We welcome applications from laboratories of any size and across all continents.

Now accepting applications for:
Cancer genomic profiling

Application period:
April 14, 2023, through June 16, 2023

A second call for applications will be announced later in 2023.

For detailed information about how to apply, including documentation requirements, the review process, and decision notification, refer to our website.